The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genmab (I)
Stock and Other Ownership Interests - Genmab (I)
Consulting or Advisory Role - Bayer; Genmab; Loxo; Roche
Research Funding - Karyopharm Therapeutics; Puma Biotechnology
Efficacy and safety of selinexor in recurrent glioblastoma.
 
Andrew B. Lassman
Honoraria - Abbvie; WebMD
Consulting or Advisory Role - Abbvie; Agios; BioClinica; Celgene; Cortice; Kadmon; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Amgen (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Pfizer (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - Agios; Karyopharm Therapeutics; Novocure
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Deciphera; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; KIYATEC; Lilly; Puma Biotechnology; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Roche (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Vascular Biogenics (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Martin J. Van Den Bent
Consulting or Advisory Role - Abbvie; Agios; Bristol-Myers Squibb; Celgene; Celldex; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst)
 
Scott Randall Plotkin
Stock and Other Ownership Interests - NFlection Therapeutics
Consulting or Advisory Role - NFlection Therapeutics
Travel, Accommodations, Expenses - AstraZeneca
 
Anna Maria Elisabeth Walenkamp
Consulting or Advisory Role - Ipsen (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Polyphor (Inst)
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Xiu Huang
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Karla Rodriguez-Lopez
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Research Funding - Karyopharm Therapeutics
Travel, Accommodations, Expenses - Karyopharm Therapeutics
 
Michael G. Kauffman
Employment - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Leadership - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Stock and Other Ownership Interests - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
 
Sharon Shacham
Employment - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Leadership - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Stock and Other Ownership Interests - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Karyopharm Therapeutics; Karyopharm Therapeutics (I)
 
Morten Mau-Sørensen
No Relationships to Disclose